News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A Nine Week Open-Label Crossover Study of Insulin Degludec (U100 and U200) and Insulin Glargine (U300) to Observe and Compare the Incidence of Hypoglycemia when Basal Insulin Administration is Changed from Evening to Morning.

Study Status:

Active

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The primary objective of this study is to observe a small sample size of patients with type 2 diabetes mellitus using insulin glargine (300 units/ml), insulin degludec (100 units/ml), and insulin degludec (200 units/ml) for the incidence and severity of hypoglycemia events from evening administration of basal insulin versus morning administration of basal insulin.

Information: 

Principal Investigator
Marcel Twahirwa, MD
Type of Trial
Prospective/Interventional
DHRHealth Institute for Research and Development
5323 S. McColl Rd., Edinburg, TX 78539
(956) 362-2390
© 2022 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram